Octagon fund discloses 955,000-share Corbus (CRBP) ownership stake

Rhea-AI Filing Summary

Octagon Capital Advisors LP, Octagon Investments Master Fund LP, and Ting Jia report a 5.4% beneficial ownership stake in Corbus Pharmaceuticals Holdings, Inc. common stock, representing 955,000 shares. The shares are held by Octagon Investments Master Fund, with Octagon as investment manager and Jia as control person.

The reporting persons share voting and dispositive power over all 955,000 shares and certify that the position was acquired and is held in the ordinary course of business, not for the purpose of changing or influencing control of Corbus Pharmaceuticals.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Corbus Pharmaceuticals Holdings, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value

(Title of Class of Securities)

21833P301

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 21833P301

1

Names of Reporting Persons

Octagon Capital Advisors LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 955,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 955,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

955,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.4 %

12

Type of Reporting Person (See Instructions)

IA, PN

SCHEDULE 13G

CUSIP No. 21833P301

1

Names of Reporting Persons

Octagon Investments Master Fund LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 955,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 955,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

955,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.4 %

12

Type of Reporting Person (See Instructions)

PN, OO

SCHEDULE 13G

CUSIP No. 21833P301

1

Names of Reporting Persons

Ting Jia

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CHINA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 955,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 955,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

955,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.4 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Corbus Pharmaceuticals Holdings, Inc.
(b)	Address of issuer's principal executive offices: 500 River Ridge Drive, Norwood, MA, 02062
Item 2.
(a)	Name of person filing: This statement is being jointly filed by: Octagon Capital Advisors LP ("Octagon") Octagon Investments Master Fund LP ("Master Fund") Ting Jia, as the principal beneficial owner of Octagon ("Dr. Jia") Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons." Octagon serves as the investment manager of the Master Fund. Dr. Jia is the managing member of Octagon. By virtue of these relationships each of Octagon and Dr. Jia may be deemed to beneficially own the Issuer's Common Shares directly owned by the Master Fund.
(b)	Address or principal business office or, if none, residence: The address of the business office of each of the Reporting Persons is 654 Madison Avenue, 21st Floor, New York, NY 10065.
(c)	Citizenship: Octagon is a Delaware limited partnership. The Master Fund is an exempted limited partnership established in the Cayman Islands. Dr. Jia is a Chinese citizen.
(d)	Title of class of securities: Common Stock, $0.0001 par value
(e)	CUSIP No.: 21833P301
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 955,000
(b)	Percent of class: 5.4%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 955,000
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 955,000 The percentage reported on this Schedule 13G is calculated based upon 17,553,037 Common Shares outstanding as of November 7, 2025, as reported in the Form 10-Q filed by the Issuer on November 12, 2025.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Octagon is the investment advisor to the Master Fund and other accounts. Dr. Jia is the control person of Octagon. The Master Fund holds the Common Shares for the benefit of its investors. The Master Fund and Octagon, for the benefit of its investors, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Shares.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Octagon Capital Advisors LP

Signature:	/s/ Ting Jia
Name/Title:	Managing Member
Date:	02/10/2026

Octagon Investments Master Fund LP

Signature:	/s/ Ting Jia
Name/Title:	Managing Member, Octagon Investments GP, LLC, its general partner
Date:	02/10/2026

Ting Jia

Signature:	/s/ Ting Jia
Name/Title:	Ting Jia
Date:	02/10/2026

FAQ

What stake in Corbus Pharmaceuticals (CRBP) is reported in this Schedule 13G/A?

The filing reports beneficial ownership of 955,000 Corbus Pharmaceuticals common shares, equal to 5.4% of the outstanding class. The percentage is based on 17,553,037 common shares outstanding as of November 7, 2025, as disclosed in Corbus’s Form 10-Q.

Who are the reporting persons in the Corbus Pharmaceuticals (CRBP) Schedule 13G/A?

The reporting persons are Octagon Capital Advisors LP, Octagon Investments Master Fund LP, and Ting Jia. Octagon is the investment manager of the Master Fund, and Jia is Octagon’s managing member and principal beneficial owner, giving them shared beneficial ownership over the reported shares.

How is voting and dispositive power over CRBP shares allocated among the reporting persons?

The filing states zero sole voting and dispositive power and 955,000 shares of shared voting and shared dispositive power. This means decisions to vote or sell the Corbus common shares are shared among the reporting persons rather than controlled individually.

On what basis is the 5.4% ownership in Corbus Pharmaceuticals (CRBP) calculated?

The 5.4% ownership figure is calculated using 17,553,037 Corbus common shares outstanding as of November 7, 2025. That outstanding share count comes from Corbus Pharmaceuticals’ Form 10-Q filed on November 12, 2025, which the reporting persons reference.

What does the certification in this Corbus (CRBP) Schedule 13G/A say about control intentions?

The certification states the securities were acquired and are held in the ordinary course of business and not for changing or influencing control of Corbus. It also confirms they are not held in connection with any transaction having that control-related purpose or effect.

Who ultimately benefits from the CRBP shares held by Octagon Investments Master Fund?

The filing explains that the Master Fund holds the Corbus common shares for the benefit of its investors. Octagon, as investment adviser, and the Master Fund have the right to receive, or direct the receipt of, dividends and sale proceeds from these shares for those investors.